Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,143.05 | 5.84 | -0.07% |
| DAX 40 | 24,900.71 | 44.24 | 0.18% |
| Dow JONES (US) | 49,098.71 | 285.30 | -0.58% |
| FTSE 100 | 10,143.44 | 6.61 | -0.07% |
| HKSE | 26,702.82 | 72.86 | 0.27% |
| NASDAQ | 23,501.24 | 65.22 | 0.28% |
| Nikkei 225 | 52,904.73 | 784.16 | -1.46% |
| NZX 50 Index | 13,460.74 | 96.13 | -0.71% |
| S&P 500 | 6,915.61 | 2.26 | 0.03% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,131.97 | 4.20 | -0.10% |